Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
The product is used to treat amyotrophic lateral sclerosis
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Nearly 6,000 patients have been treated with the drug since 2017
Subscribe To Our Newsletter & Stay Updated
